Stockscreener 앱 받기
9.05
43.48%
2.84
전일 마감가:
$6.21
열려 있는:
$14.745
하루 거래량:
21.52M
Relative Volume:
3.67
시가총액:
$4.50M
수익:
-
순이익/손실:
$-8.74M
주가수익비율:
-4.4146
EPS:
-2.05
순현금흐름:
$-8.25M
1주 성능:
+43.02%
1개월 성능:
+6,584%
6개월 성능:
+72.68%
1년 성능:
-78.68%
1일 변동 폭
$8.54
$15.90
1주일 범위
$5.94
$15.90
52주 변동 폭
$0.0927
$62.60
Glucotrack Inc Stock (GCTK) Company Profile
명칭
Glucotrack Inc
전화
972 (8) 675-7878
주소
301 RT 17 NORTH, RUTHERFORD
GCTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
9.0422 | 4.50M | 0 | -8.74M | -8.25M | -2.05 |
|
ISRG
Intuitive Surgical Inc
|
522.18 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
170.54 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.39 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
258.28 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
221.08 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Glucotrack Inc 주식(GCTK)의 최신 뉴스
Glucotrack announces 1:60 reverse stock split - Investing.com
GlucoTrack Implements Reverse Stock Split - TipRanks
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements - mx.advfn.com
Glucotrack announces 1-for-60 reverse stock split effective June 16 By Investing.com - Investing.com South Africa
Glucotrack announces 1-for-60 reverse stock split effective June 16 - Investing.com Nigeria
GlucoTrack Announces 1-for-60 Reverse Stock Split - TipRanks
Glucotrack Implements Major 1-for-60 Reverse Split: What This Means for Your Investment - Stock Titan
Glucotrack’s Innovative Approach to Diabetes Management Sets New Standards - citybuzz -
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management - Nasdaq
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions - mx.advfn.com
GlucoTrack to Present at ADA Scientific Sessions - TipRanks
Revolutionary Diabetes Tech: Glucotrack's 3-Year Implantable Monitor Eliminates Daily Finger Pricks - Stock Titan
GCTK stock plunges to 52-week low, hits $0.13 By Investing.com - Investing.com South Africa
GCTK stock plunges to 52-week low, hits $0.13 - Investing.com India
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives - The Globe and Mail
Glucotrack appoints new board member with diabetes tech expertise By Investing.com - Investing.com South Africa
Glucotrack appoints new board member with diabetes tech expertise - Investing.com
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD - The Manila Times
GlucoTrack (NASDAQ:GCTK) Trading Down 0.2% – Time to Sell? - Defense World
GlucoTrack Approves Key Proposals at Annual Meeting - TipRanks
GCTK stock plunges to 52-week low, touches $0.13 - Investing.com Australia
GCTK stock plunges to 52-week low, touches $0.13 By Investing.com - Investing.com Nigeria
GlucoTrack Establishes Patient Advisory Board for CBGM - TipRanks
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development - The Manila Times
Glucotrack, Inc. Forms Patient Advisory Board to Enhance Development of Continuous Blood Glucose Monitor - Nasdaq
Groundbreaking 3-Year Implantable Glucose Monitor Gets Patient-Led Development at Glucotrack - Stock Titan
Glucotrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Innovative Continuous Blood Glucose Monitor Shows Promise in First Human Trial - citybuzz -
GlucoTrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack, Inc. SEC 10-Q Report - TradingView
Glucotrack, Inc. Advances Continuous Blood Glucose Monitoring Technology with Clinical Study Initiation in Australia by Q3 2025 - Nasdaq
Glucotrack Reports First Quarter 2025 Financial Results And Recent Corporate Highlights - marketscreener.com
Breakthrough: Glucotrack's Implantable Diabetes Monitor Hits Clinical Milestone, FDA Decision Expected Q4 - Stock Titan
Glucotrack gains HREC approval for clinical study of CBGM device - Yahoo Finance
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients - FinancialContent
Certain Options of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
GlucoTrack Gains Approval for Long-Term Clinical Study - TipRanks
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor - The Manila Times
Geode Capital Management LLC Increases Stock Holdings in GlucoTrack, Inc. (NASDAQ:GCTK) - Defense World
GlucoTrack Inc (GCTK) can make a big difference with a little luck - Sete News
Medtech CEO Shares Lessons From FIH Implantable Glucose Monitor Trial - Clinical Leader
GlucoTrack Releases Investor Presentation on April 29 - TipRanks
GlucoTrack Inc (NASDAQ:GCTK) stock crossing the finish line today - uspostnews.com
Can GlucoTrack Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Now Is The Time To Build A Position In GlucoTrack Inc (NASDAQ:GCTK) - Marketing Sentinel
Glucotrack Inc (GCTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
0.11%
자본화:
|
볼륨(24시간):